get a key
steadybase-$ company SCNI
account_id none on file
legal_name Scinai Immunotherapeutics Ltd.
ticker SCNI
cik 1611747
domain scinai.com
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
calls 0 filings 6 executives 0 family 0
why_nownone on file
callsnone on file
filings
In addition, travel restrictions, security concerns or government-imposed limitations on movement may impair our ability to conduct business activities, including interactions with customers, partners and suppliers.

filing / Apr 1, 2026 / receipt

Such events may result in travel restrictions, workforce disruptions, supply chain interruptions, limitations on business operations or other government-imposed measures that could negatively impact our activities.

filing / Apr 1, 2026 / receipt

Severance expense for the years ended December 31, 2025, 2024 and 2023, amounted to $ 161 , 163 $ and $ 182 , respectively.

filing / Apr 1, 2026 / receipt

● Leveraging CDMO operations to support R&D and reduce costs: Our CDMO activities enable us to utilize our manufacturing infrastructure, generate revenues, and support our internal programs, thereby helping to absorb fixed costs and reduce overall cash burn.

filing / Apr 1, 2026 / receipt

obtain additional financing, reduce costs and manage our liabilities as they become due. There can be no assurance that we will be able

filing / Apr 1, 2026 / receipt

The original lease term of the office space was 10 years and on December 24, 2024, the Company exercised its option to extend the lease for an additional five years which ends at December 31, 2032.

filing / Apr 1, 2026 / receipt

executivesnone on file
familynone on file
upcoming
2026-11-23 earnings call scheduled ir
changesnone on file
mcp_package_hint
steadybase-$